In a landmark ruling, Delaware’s Supreme Court vacated approximately $700 million of a previously awarded $1 billion damages claim against Johnson & Johnson for its alleged breach of the 2019 merger agreement to acquire Auris Health. The court determined that J&J properly disclosed its seven-month extension option and did not materially mislead Auris Health shareholders. As a result, J&J’s potential cash outlay related to the Auris acquisition dispute has shrunk by nearly 70%, significantly lowering legal contingent liability on its balance sheet and removing a key overhang on its medical devices segment valuation.

During J&J’s presentation at the 44th Annual J.P. Morgan Healthcare Conference, CEO Joaquin Duato highlighted the company’s 2025 outperformance—driven by broad-based strength across pharmaceuticals, medtech and consumer health—and projected that 2026 revenues will exceed 2025 levels. He confirmed full-year double-digit revenue growth visibility in the latter half of the decade, emphasizing that J&J is on track to surpass $100 billion in annual sales. Duato reiterated priorities including continued investment in oncology and immunology pipelines, expansion of robotic surgery applications and disciplined capital allocation to drive margins above historical mid-teens percentages.

Johnson & Johnson Innovation – JJDC, the company’s venture arm, led a strategic tranche in Distalmotion’s Series G funding to accelerate rollout of the DEXTER robotic surgery system in ambulatory surgery centers. The move follows JJDC’s broader commitment of over $250 million into soft-tissue robotics since 2023. DEXTER’s small footprint and integration with existing OR technologies address the fastest-growing outpatient segment, where more than 2.5 million procedures are performed annually. With over 3,000 patients treated in clinical practice, J&J’s backing positions it to capture a larger share of the emerging ASC robotics market and reinforce its medtech leadership.